# CQ14 Validation Retrospective: The TP53-TYMS Synthetic Lethality Journey

**Date**: January 14, 2026
**Competency Question**: CQ14 - Feng et al. Synthetic Lethality Validation
**Group ID**: `cq14-feng-synthetic-lethality`

---

## The Mission

Validate synthetic lethal gene pairs from Feng et al. (2022) and identify druggable opportunities for TP53-mutant cancers. The question: Can we build a knowledge graph that traces from genetic vulnerability (TP53 mutation) through metabolic target (TYMS) to clinical intervention (approved drugs and active trials)?

---

## Phase 1: Anchor - Gene Resolution

Following the Fuzzy-to-Fact protocol, I first resolved the core entities:

| Gene | HGNC ID | Entrez | UniProt | Ensembl |
|------|---------|--------|---------|---------|
| TP53 | HGNC:11998 | 7157 | P04637 | ENSG00000141510 |
| TYMS | HGNC:12441 | 7298 | P04818 | ENSG00000176890 |

The MCP tools (`hgnc_search_genes`, `hgnc_get_gene`) provided canonical identifiers with cross-references that proved critical for downstream validation.

---

## Phase 2: Enrich - Protein Context

UniProt enrichment revealed the mechanistic foundation:

- **TP53**: "Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis... Acts as tumor suppressor... Apoptosis induction mediated by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression."

- **TYMS**: "Catalyzes the reductive methylation of dUMP to dTMP... contributes to de novo mitochondrial thymidylate biosynthesis pathway."

This established the biochemical link: TP53 regulates cell cycle in response to DNA damage. TYMS provides the thymidine essential for DNA synthesis. In TP53-mutant cells, the checkpoint is gone - they cannot arrest when thymidine is depleted.

---

## Phase 3: Expand - Interaction Networks

### BioGRID Results
The `biogrid_get_interactions` tool returned 50 interactions for TYMS including:
- **CHEK1-TYMS**: Negative Genetic interaction (PubMed: 28319113)

A "Negative Genetic" interaction indicates synthetic lethality - when both genes are perturbed, the combined effect is worse than expected.

### STRING Results
STRING confirmed TYMS sits at the hub of nucleotide biosynthesis:
- DHFR (score: 0.958) - regenerates tetrahydrofolate
- DUT (score: 0.955) - provides dUMP substrate
- DTYMK (score: 0.990) - downstream kinase
- MTHFD1 (score: 0.965) - one-carbon metabolism

---

## Phase 4: Target Traversal - Druggability

ChEMBL confirmed approved TYMS inhibitors:

| Drug | ChEMBL ID | Max Phase | Mechanism |
|------|-----------|-----------|-----------|
| Fluorouracil | CHEMBL:185 | 4 | TYMS inhibitor (covalent via FdUMP) |
| Pemetrexed | CHEMBL:225072 | 4 | Multi-folate inhibitor (TYMS + DHFR + GARFT) |

The curl command to ChEMBL `/mechanism` endpoint confirmed CHEMBL:1952 (Thymidylate synthase) as the target.

---

## Phase 5: Clinical Landscape

ClinicalTrials.gov search revealed:
- **58 recruiting Phase 3 trials** using pemetrexed in lung cancer
- **NCT:06976892** (IDOL trial): Idetrexed + Olaparib for ovarian cancer

---

## The Validation Journey: Finding the Error

At this point, the research seemed complete. But when asked to validate findings using independent agents, the process revealed something important.

### Parallel Validation Agents Deployed

I launched 4 agents simultaneously:
1. **Gene Identifier Validator** - Cross-check HGNC, Ensembl, UniProt
2. **Drug-Target Mechanism Validator** - Verify ChEMBL relationships
3. **Clinical Trial Validator** - Confirm trial counts and NCT IDs
4. **Synthetic Lethality Evidence Validator** - Check BioGRID and literature

### The Discovery

**Agent 3 (Clinical Trials)** found a typo:
- My claimed NCT ID: `NCT:06975892` (does not exist)
- Correct NCT ID: `NCT:06976892` (verified)
- Error: Fifth digit was `5` instead of `6`

This is exactly the kind of error that propagates through knowledge graphs. A single digit flip renders a citation invalid. Without validation, this would have persisted as a broken reference.

### The Bonus Discovery

**Agent 4 (Synthetic Lethality)** found evidence I hadn't seen in my initial research:

> **Direct TP53-TYMS negative genetic interaction in BioGRID** (PubMed: 35559673, 2022)

This means the synthetic lethality between TP53 and TYMS isn't just theoretical - it's experimentally validated from genome-wide CRISPR screens. The validation agent discovered more than it was asked to find.

---

## External Validation: The Gemini Cross-Check

Sending findings to Gemini for review added another layer:

1. **Confirmed** the thymidylateless death mechanism
2. **Explained** why the CHEK1 connection matters (TP53-deficient cells rely on intra-S/G2M checkpoints)
3. **Highlighted** the "dual synthetic lethality" in the IDOL trial (TYMS + PARP inhibition)
4. **Suggested** investigating p21 (CDKN1A) and GADD45A as mediators

This led to additional research confirming p21's STRING interactions with CDK2/CDK4/CDK6 (scores: 0.999) - the cyclin-dependent kinases that p21 inhibits to arrest the cell cycle.

---

## The Triple Threat Mechanism

The validated knowledge graph reveals why TP53-mutant cells are exquisitely vulnerable to TYMS inhibition:

```
                                   TP53 MUTATION
                                        |
                                        v
                    +-------------------+-------------------+
                    |                   |                   |
                    v                   v                   v
            [No p21 induction]   [No GADD45A]      [No G1/S arrest]
                    |                   |                   |
                    v                   v                   v
            [CDK2 active]      [No DNA repair]     [Cell enters S-phase]
                    |                   |                   |
                    +-------------------+-------------------+
                                        |
                                        v
                              TYMS INHIBITION (5-FU, Pemetrexed)
                                        |
                                        v
                              Thymidine Depletion
                                        |
                                        v
                              DNA Replication Catastrophe
                                        |
                                        v
                              THYMIDYLATELESS DEATH
```

The IDOL trial (NCT:06976892) adds Olaparib to block PARP-mediated repair of the resulting DNA breaks - a "triple threat" against TP53-mutant ovarian cancer.

---

## Validated Knowledge Graph Nodes

| Entity | CURIE | Type |
|--------|-------|------|
| TP53 | HGNC:11998 | Gene |
| TYMS | HGNC:12441 | Gene |
| CDKN1A (p21) | HGNC:1784 | Gene |
| GADD45A | HGNC:4095 | Gene |
| CHEK1 | (BioGRID) | Gene |
| Fluorouracil | CHEMBL:185 | Compound |
| Pemetrexed | CHEMBL:225072 | Compound |
| Idetrexed | (Clinical trial) | Compound |
| Olaparib | (Clinical trial) | Compound |
| Thymidylate synthase | CHEMBL:1952 | Target |
| DHFR | CHEMBL:202 | Target |
| IDOL Trial | NCT:06976892 | Trial |

## Validated Edges

| Source | Relationship | Target | Evidence |
|--------|--------------|--------|----------|
| TP53 | SYNTHETIC_LETHAL_WITH | TYMS | BioGRID (PubMed: 35559673) |
| CHEK1 | NEGATIVE_GENETIC | TYMS | BioGRID (PubMed: 28319113) |
| Fluorouracil | INHIBITS | TYMS | ChEMBL mechanism |
| Pemetrexed | INHIBITS | TYMS | ChEMBL mechanism |
| Pemetrexed | INHIBITS | DHFR | ChEMBL mechanism |
| p21 | INHIBITS | CDK2 | STRING (score: 0.999) |
| TP53 | ACTIVATES | p21 | UniProt function |
| TP53 | ACTIVATES | GADD45A | UniProt function |
| TYMS | INTERACTS_WITH | DHFR | STRING (score: 0.958) |
| TYMS | INTERACTS_WITH | DUT | STRING (score: 0.955) |

---

## Lessons Learned

1. **Validation catches errors that propagate**: A single-digit typo in an NCT ID would have created a broken citation. Parallel validation agents caught it.

2. **Validation discovers more than it's asked**: The synthetic lethality validator found direct TP53-TYMS evidence from BioGRID that strengthened the research.

3. **Cross-validation with different models provides different perspectives**: Gemini highlighted the mechanistic importance of p21 and GADD45A that I hadn't fully explored.

4. **The Fuzzy-to-Fact protocol works**: Starting with fuzzy gene names, resolving to CURIEs, enriching with protein context, expanding through interaction networks, and traversing to drugs created a traceable knowledge graph.

---

## Next Steps

1. **Explore resistance mechanisms**: SLC19A1 (reduced folate carrier) overexpression
2. **Map FOLR1 expression**: Alpha-folate receptor density in ovarian cancer lines (SK-OV-3, OVCAR-3) relevant to Idetrexed targeting

---

*Validation Date: 2026-01-14*
*Validated by: Claude Opus 4.5 with parallel subagents*
*Cross-validated by: Gemini*
